Key Highlights

  • AbbVie shares were trading down 1.35% at $247.54 intraday, extending Friday's post-earnings decline.
  • The move comes despite Wall Street analysts largely reiterating bullish views following the company's Q2 beat.
  • Investor focus is shifting toward AbbVie's pipeline, including trispecific candidates and Emtamig data, alongside the dilutive pending Aptevo Therapeutics acquisition.

What's Happening With the Stock

AbbVie (NYSE:ABBV) shares were trading down 1.35% at $247.54 intraday, with a day range of $244.71 to $256.20 on volume of 4.16 million shares, extending a decline that began following the company's second-quarter earnings report last week. Despite the pullback, Wall Street analysts have largely reiterated bullish views on the stock.

RBC highlighted what it called a strong operational quarter, pointing to resilient growth in Skyrizi and Rinvoq despite emerging competition in the immunology space. Cantor Fitzgerald lifted its price target to $258 while maintaining a Neutral rating, and Oppenheimer raised its target to $285 with an Overweight rating, both moves suggesting continued confidence in the underlying business even as shares have pulled back.

AbbVie's second-quarter results showed adjusted earnings per share of $3.65, beating the $3.64 estimate, on net revenue of nearly $17 billion, up 10.2% operationally, driven by strong double-digit growth from both Skyrizi and Rinvoq, each growing more than 20%. The company raised its full-year revenue guidance by $300 million to approximately $67.6 billion and updated its adjusted EPS guidance to $13.87 to $14.07, reflecting $0.10 of upside from business momentum offset by $0.14 of dilution from the pending Aptevo Therapeutics acquisition.

Pipeline and Dilution Concerns

Investor focus is increasingly shifting toward AbbVie's pipeline, including trispecific antibody candidates and data expected later this year from Emtamig, alongside the dilutive impact of the pending Aptevo Therapeutics acquisition, expected to close in the third quarter. Key pipeline highlights include a Skyrizi subcutaneous induction filing for Crohn's disease under FDA review, with a decision expected in the fall of 2026, and Rinvoq's European approval for vitiligo and alopecia areata, with U.S. decisions anticipated for indications that could approach $2 billion in combined peak sales.

For the third quarter, AbbVie guided net revenues of approximately $17.2 billion and adjusted EPS between $3.84 and $3.88, which includes partial Aptevo dilution but excludes acquired in-process research and development expense. Full-year adjusted research and development expense guidance was raised to approximately $9.8 billion, and selling, general and administrative expense guidance was raised to approximately $14.5 billion, with operating margin approaching 47% of sales.

Valuation Context

AbbVie's market capitalization stood at $437.35 billion intraday, with shares trading at a trailing price-to-earnings ratio of 24.29 and a dividend yield of 2.77%. The stock's 52-week range spans $190.75 to $267.47. The company maintains strong balance sheet flexibility, with a stated commitment to reach a net leverage ratio of 2 times within two to three years post-Apigee close, while continuing to pursue additional business development opportunities in immunology, neuroscience, and oncology.

Conclusion

AbbVie's continued pullback despite a genuine earnings beat and largely bullish analyst commentary suggests investors are focused on the near-term dilutive impact of the Aptevo acquisition and looking for confirmation that the company's pipeline, including its trispecific candidates and Rinvoq's expanding indications, can sustain growth as Skyrizi and Rinvoq mature.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.